Q3 Earnings Estimate for KALV Issued By Leerink Partnrs

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report issued on Monday, November 4th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceutical company will earn $0.81 per share for the quarter, up from their previous forecast of ($0.92). The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.19) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($1.66) EPS and FY2026 earnings at ($2.26) EPS.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04.

A number of other brokerages have also commented on KALV. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. Finally, Needham & Company LLC restated a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 6th.

KalVista Pharmaceuticals Trading Down 2.0 %

NASDAQ KALV opened at $11.18 on Thursday. The company’s fifty day simple moving average is $11.48 and its 200-day simple moving average is $12.08. The stock has a market cap of $483.20 million, a P/E ratio of -3.17 and a beta of 0.92. KalVista Pharmaceuticals has a 52 week low of $7.21 and a 52 week high of $16.88.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently bought and sold shares of the business. Capital World Investors acquired a new stake in shares of KalVista Pharmaceuticals during the 1st quarter worth approximately $17,370,000. Great Point Partners LLC bought a new position in KalVista Pharmaceuticals during the 2nd quarter worth $15,768,000. Entropy Technologies LP bought a new position in KalVista Pharmaceuticals during the 1st quarter worth $121,000. The Manufacturers Life Insurance Company increased its position in KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 3,314 shares during the period. Finally, Emerald Advisers LLC lifted its stake in KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after buying an additional 192,091 shares during the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 7,352 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $12.19, for a total transaction of $89,620.88. Following the transaction, the chief executive officer now owns 250,800 shares of the company’s stock, valued at approximately $3,057,252. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the sale, the insider now directly owns 83,745 shares of the company’s stock, valued at approximately $1,038,438. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 7,352 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $12.19, for a total transaction of $89,620.88. Following the completion of the transaction, the chief executive officer now directly owns 250,800 shares of the company’s stock, valued at $3,057,252. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,804 shares of company stock valued at $372,112. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).